Archives
-
CD28–ARS2–PKM Splicing and CD8+ T-Cell Metabolism
2026-09-17
The reference study identifies a CD28–ARS2 signaling axis that rewires alternative splicing of PKM in activated CD8+ T cells, favoring PKM2 and enabling flexible glucose metabolism, cytokine production, and antitumor activity. Its findings separate this splicing-dependent pathway from canonical CD28–PI3K signaling and provide a framework for integrating transcript, metabolic, and functional measurements.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-17
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for controlled studies of CDK9-dependent transcription elongation and exploratory HIV-1 propagation inhibition. It should not be treated as a pan-CDK reagent, a general cell-cycle inhibitor, or a basis for therapeutic conclusions.
-
DiscoveryProbe Protease Inhibitor Library: Assay Logic
2026-09-16
The DiscoveryProbe Protease Inhibitor Library supports protease inhibition studies from primary biochemical screening through cellular mechanism validation. This article presents an assay-decision framework that connects library composition, artifact control, orthogonal confirmation, and translational interpretation.
-
G007-LK Tankyrase 1/2 Inhibitor Workflow
2026-09-16
Build reproducible Wnt, β-catenin, and Hippo-pathway experiments with G007-LK, from concentration-response assays to mechanistic validation. This workflow connects APC-mutant colorectal cancer models with hepatocellular carcinoma assays while emphasizing controls, formulation, and troubleshooting.
-
Ertugliflozin Cardiovascular Outcomes in Type 2 Diabetes
2026-09-15
The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its rigorous endpoint hierarchy, long follow-up, and dose-pooled analysis provide a useful framework for interpreting cardiovascular, heart-failure, and renal signals in diabetes mellitus research.
-
U0126 and Adaptive Resistance in MEK1/2 Assays
2026-09-15
U0126 is a MEK1/2 inhibitor that reveals how MAPK/ERK blockade can be bypassed through AKT-dependent resistance. This article translates mechanistic findings on HDAC8, PLCB1, and DESC1 into a resistance-aware framework for cancer biology research and pathway assays.
-
Multiplex PBMC Flow Cytometry for Immunomodulator Screening
2026-09-14
Brox and Hackstein developed and validated a multiplex flow cytometry assay that measures T-cell proliferation and activation together with B-cell costimulatory responses in human PBMCs. The study shows how defined stimulation conditions, multiparametric readouts, and Z-factor validation can improve the physiological relevance and interpretability of immunomodulator screening.
-
GDC-0941 for PI3K/Akt Resistance Studies
2026-09-14
GDC-0941 provides a practical way to connect PI3K/Akt signaling with therapy resistance, cancer cell proliferation inhibition, and stem-like phenotypes. This workflow combines rapid pAKT pathway readouts with longer-term viability, apoptosis, β-catenin localization, and in vivo validation strategies.
-
EdU Imaging Kits (Cy3) for S-Phase Analysis
2026-09-13
EdU Imaging Kits (Cy3) use 5-ethynyl-2'-deoxyuridine and CuAAC labeling to measure DNA synthesis in S-phase cells without DNA denaturation. The K1075 workflow supports fluorescence microscopy and flow cytometry while preserving cellular morphology and antigen-binding sites.
-
Nanospikes Trigger Lysosomal Autophagy Cell Death
2026-09-12
The reference study shows that gold nanospike geometry can tune intracellular mechanical stress and induce lysosomal membrane disruption, with 254.2 nm spikes producing the strongest anticancer effect. Its combination of nanostructure engineering, finite element modeling, organelle-level analysis, and in vivo validation provides a framework for designing mechanically active cancer therapeutics.
-
Sodium Overload Rewires Mitochondrial Energy in NECSO
2026-09-11
Qiao and colleagues show that TRPM4-driven sodium influx causes necrosis by disrupting mitochondrial sodium–calcium exchange, oxidative phosphorylation, and TCA-cycle activity. The study places mitochondrial energy failure upstream of Na/K-ATPase collapse, providing a mechanistic framework for understanding sodium-overload necrosis and related bioenergetic injury.
-
Cannabidiol, FAAH, and Orofacial Pain
2026-09-11
This study shows that cannabidiol (CBD) can reduce both inflammatory orofacial nociception and pain-associated affective and cognitive deficits in mouse models. Its mechanistic contribution is the integration of peripheral FAAH–endocannabinoid regulation, central CB1-linked signaling, and serotonin dynamics in the central amygdala.
-
Palonosetron for Preventing Chemotherapy-Induced Nausea
2026-09-10
Ruhlmann and Herrstedt review palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting, emphasizing its high receptor affinity, allosteric binding, and potential advantages in delayed symptom control. The review also shows why pharmacologic distinctions must be judged against comparative clinical outcomes, tolerability, and the broader antiemetic regimen.
-
Aurora A in High-Risk Retinoblastoma
2026-09-10
A 2024 American Journal of Pathology study found that Aurora kinase A is frequently overexpressed in retinoblastoma and associated with histopathologic features linked to poor outcome and chemotherapy resistance. By combining patient-tissue profiling with genetic depletion, pharmacologic inhibition, patient-derived models, and xenografts, the work supports AURKA as a functionally relevant target while highlighting the need for disease-specific validation and ocular delivery studies.
-
Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
2026-09-09
Phosphatase Inhibitor Cocktail (SKU K1015) helps limit post-lysis dephosphorylation during protein extraction and downstream phosphorylation assays. It is intended for research workflows such as immunoblotting, immunoprecipitation, kinase activity assays, and mass spectrometry, not diagnostic or medical use.